Research Analysts’ Weekly Ratings Updates for Express Scripts (ESRX)

Several analysts have recently updated their ratings and price targets for Express Scripts (NASDAQ: ESRX):

  • 5/17/2018 – Express Scripts was given a new $92.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 5/11/2018 – Express Scripts was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/4/2018 – Express Scripts was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 5/3/2018 – Express Scripts had its price target lowered by analysts at Leerink Swann from $90.00 to $80.00. They now have a “market perform” rating on the stock.
  • 5/3/2018 – Express Scripts had its price target lowered by analysts at Barclays from $84.00 to $83.00. They now have an “equal weight” rating on the stock.
  • 5/2/2018 – Express Scripts was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 5/1/2018 – Express Scripts was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Express Scripts recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. Moreover, the company faces stiff competition, which raises concern. The company recently announced that it is getting acquired by Cigna Corporation, a global health insurance company. However, it has been benefitting from a rise in patient claims and strong customer retention. Express Scripts’ solid guidance for 2018 holds promise. Express Scripts' pharmacy-benefit management segment (PBM) coupled with recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. In the past six months, Express Scripts has outperformed the industry in terms of price.”
  • 4/26/2018 – Express Scripts was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 4/26/2018 – Express Scripts was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 4/2/2018 – Express Scripts was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

ESRX stock opened at $76.35 on Friday. The company has a current ratio of 0.69, a quick ratio of 0.56 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $41.42 billion, a price-to-earnings ratio of 10.75, a P/E/G ratio of 0.93 and a beta of 0.98. Express Scripts has a 1 year low of $73.16 and a 1 year high of $73.65.

Express Scripts (NASDAQ:ESRX) last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $1.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.76 by $0.01. The company had revenue of $24.77 billion for the quarter, compared to analyst estimates of $24.80 billion. Express Scripts had a return on equity of 25.41% and a net margin of 4.59%. Express Scripts’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter last year, the company earned $1.33 EPS. equities analysts forecast that Express Scripts will post 9.07 EPS for the current fiscal year.

In other Express Scripts news, insider Christine Houston sold 19,889 shares of the stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $76.69, for a total value of $1,525,287.41. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Everett Neville sold 4,895 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $75.26, for a total value of $368,397.70. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of ESRX. Swedbank purchased a new position in shares of Express Scripts in the 4th quarter valued at about $111,016,000. Leucadia National Corp purchased a new position in shares of Express Scripts in the 4th quarter valued at about $567,000. Xact Kapitalforvaltning AB increased its holdings in shares of Express Scripts by 5.2% in the 4th quarter. Xact Kapitalforvaltning AB now owns 102,730 shares of the company’s stock valued at $7,668,000 after acquiring an additional 5,123 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Express Scripts by 1.6% in the 4th quarter. Glenmede Trust Co. NA now owns 422,156 shares of the company’s stock valued at $31,508,000 after acquiring an additional 6,448 shares during the last quarter. Finally, Two Sigma Securities LLC purchased a new position in shares of Express Scripts in the 4th quarter valued at about $406,000. 88.20% of the stock is currently owned by institutional investors.

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Set UDG Healthcare  Target Price at $832.00
Brokerages Set UDG Healthcare Target Price at $832.00
First Savings Financial Group  Given Daily Coverage Optimism Score of 0.04
First Savings Financial Group Given Daily Coverage Optimism Score of 0.04
Brokerages Anticipate Ferro Co.  Will Announce Earnings of $0.45 Per Share
Brokerages Anticipate Ferro Co. Will Announce Earnings of $0.45 Per Share
Favorable News Coverage Somewhat Unlikely to Impact Alliance One International  Share Price
Favorable News Coverage Somewhat Unlikely to Impact Alliance One International Share Price
Hastings Group Hldg PLC  Receives GBX 295.70 Average PT from Brokerages
Hastings Group Hldg PLC Receives GBX 295.70 Average PT from Brokerages
PrimeEnergy  Getting Somewhat Positive Press Coverage, Report Shows
PrimeEnergy Getting Somewhat Positive Press Coverage, Report Shows


Leave a Reply

© 2006-2018 Ticker Report. Google+.